|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Insight: Inflammatory Bowel Disease - Debate over early aggressive treatment continues
Datamonitor, Dec 2007, Pages: 297
Inflammatory bowel disease (IBD) is a chronic inflammatory condition that affects the gastrointestinal tract causing a number of distressing symptoms such as bleeding, diarrhea and abdominal pain. IBD includes key subsets Crohns disease and ulcerative colitis, both of which can significantly impact on the quality of life of an individual.
Scope
- Analysis of the inflammatory bowel disease market based on a survey of 180 gastroenterologists supported by key opinion leader interviews
- Overview of epidemiology and patient segmentation in IBD
- Influences on gastroenterologists prescribing behavior and their perception of current brands such as Remicade, Humira, Pentasa, Asacol and Lialda
- Assessment of outcomes of treatment with Remicade focusing on treatment failure and reasons for failure
Highlights of this title
Clinical guidelines recommend a step-up treatment approach. However, Datamonitors survey suggests that currently 20% of patients with severe IBD currently receive an early aggressive treatment approach. There is an ongoing debate among Gastroenterologists and Datamonitor believe this approach will become more commonplace in the future.
Remicade remains the first choice biologic therapy in 80% of biologic-naïve patients. However, Humira has distinct advantages over Remicade that will lead to strong. Humira is positioned as a treatment for Remicade-failure patients, but Datamonitors survey suggests currently only 30% of these patients go on to receive Humira.
Shires Lialda (mesalazine), recently launched as a once-daily drug, is perceived by gastroenterologists to perform well on patient compliance. In a drug class where there is little differentiation between brands over efficacy and safety, Lialda will provide a clinical advantage thanks to its improved dosing regimen.
Key reasons to purchase this title
- Target prescribers more effectively, through an understanding of prescribing behavior and influencing factors
- Validate new product forecasting based on diagnosis and treatment rates, and the likely rate of uptake for new products
- Benchmark brand awareness and perceptions surrounding product positioning in order to formulate competitive lifecycle management strategies
Customers who bought this item also bought
Commercial Insight: Inflammatory Bowel Disease - Convenience and Compliance Drive Market Success
Forecast Insight: Inflammatory Bowel Disease - New product launches sustain long-term market growth
Commercial and Pipeline Insight: Inflammatory Bowel Disease - Competition Increases for the Biologics
Strategic Perspectives: Inflammatory Bowel Disease - The Rise of Remicade
Physician Perception of Biologics in Autoimmune Disease - Targeted Detailing is the Key to Success
Ulcerative Colitis Therapy Area Pipeline Report
Digestive System - Ulcerative Colitis Drug Pipeline Report
Therapeutic Clinical Intelligence - Inflammatory Bowel Disease
Digestive System Ulcerative Colitis
Stakeholder Insight: Parkinsons Disease - Evidence of neuroprotection essential to progress treatment dynamics
Commercial and Pipeline Perspectives: Lower GI Disorders - Remicade Leads Growth as Novel Biologics Compete for Market Share in Inflammatory Bowel Disease
Disease Management and Drug Adherence: Strategies to support patients and enhance treatment persistence
|
|
|
|
